News
Both contracts slumped 1.7% on Wednesday as investors doubted that the upcoming trade talks will result in a breakthrough.
OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results